E6007 + E6007 + E6007 + E6007 + E6007 + E6007
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Inflammatory Bowel Disease
Conditions
Inflammatory Bowel Disease
Trial Timeline
Sep 1, 2010 → —
NCT ID
NCT01221818About E6007 + E6007 + E6007 + E6007 + E6007 + E6007
E6007 + E6007 + E6007 + E6007 + E6007 + E6007 is a phase 1 stage product being developed by Eisai for Inflammatory Bowel Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01221818. Target conditions include Inflammatory Bowel Disease.
What happened to similar drugs?
8 of 20 similar drugs in Inflammatory Bowel Disease were approved
Approved (8) Terminated (2) Active (12)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01221818 | Phase 1 | Completed |
Competing Products
20 competing products in Inflammatory Bowel Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Infliximab + Infliximab + Infliximab | Celltrion | Approved | 50 |
| CT-P13 | Celltrion | Phase 3 | 36 |
| Subcutaneous infliximab CT-P13 Remsima®SC | Celltrion | Pre-clinical | 22 |
| Infliximab subcutaneous + Immunosuppressive Agents | Celltrion | Phase 3 | 47 |
| fidaxomicin | Astellas Pharma | Approved | 43 |
| Eribulin + Adriamycin + Cyclophosphamide | Eisai | Phase 2 | 39 |
| Placebo + MORF-057 | Eli Lilly | Phase 2 | 42 |
| Baricitinib + Baricitinib | Eli Lilly | Phase 2 | 35 |
| LY3114062 SC + Placebo + LY3114062 IV | Eli Lilly | Phase 1 | 29 |
| MORF-057 + Placebo | Eli Lilly | Phase 2 | 39 |
| MORF-057 | Eli Lilly | Phase 2 | 35 |
| LY3009104 | Eli Lilly | Phase 1 | 29 |
| HRF2105 patch + Loxoprofen patch + placebo | Jiangsu Hengrui Medicine | Phase 2 | 31 |
| Risankizumab | AbbVie | Approved | 43 |
| GC012F Injection infusion | AstraZeneca | Phase 1 | 36 |
| AZD6793 + Placebo | AstraZeneca | Phase 1 | 29 |
| Human Papillomavirus Vaccine | Merck | Approved | 43 |
| Pembrolizumab | Merck | Phase 2 | 31 |
| Gardasil vaccine | Merck | Pre-clinical | 26 |
| Bezlotoxumab | Merck | Approved | 35 |